Compare AGD & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGD | ALDX |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.1M | 293.0M |
| IPO Year | N/A | 2014 |
| Metric | AGD | ALDX |
|---|---|---|
| Price | $11.71 | $4.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 61.2K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.20 | $1.14 |
| 52 Week High | $9.78 | $7.20 |
| Indicator | AGD | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 49.88 |
| Support Level | $11.39 | $3.94 |
| Resistance Level | $11.52 | $5.68 |
| Average True Range (ATR) | 0.15 | 0.42 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 77.03 | 57.93 |
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors among others.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.